AsthmaMar 15, 2026
About half of severe asthma cases share a single underlying driver: too many eosinophils, a type of white blood cell that floods the airways, fuels relentless inflammation, and doesn't respond well to standard inhalers. This subtype, called eosinophilic asthma, is now one of the clearest success stories in precision medicine. A simple blood test can flag it, and targeted biologic drugs can dramatically reduce flare-ups, improve lung function, and even make long-term remission a realistic goal.
The catch? Many people with poorly controlled asthma still haven't been tested for it. If your asthma developed in adulthood, resists high-dose inhalers, or comes with nasal polyps, this is worth understanding.
Respiratory HealthMar 15, 2026
For years, a real concern hung over this drug: could adding a long-acting bronchodilator to an inhaled steroid increase the risk of serious asthma events? Large randomized controlled trials in adolescents and adults have now answered that clearly. Fluticasone salmeterol does not raise the risk of asthma-related deaths, intubations, or hospitalizations compared to fluticasone alone. What it does is reduce severe exacerbations by roughly 20 to 21%.
In COPD, the picture is more complicated. The symptom benefits hold up, but fluticasone salmeterol consistently increases pneumonia risk. Same drug, meaningfully different risk profiles depending on the disease being treated.
Acid-Base BalanceMar 15, 2026
A low CO₂ result on a standard blood panel can mean your body is struggling with a serious acid-base problem. Or it can mean the lab tech left your blood sample sitting uncapped too long. The value can drop more than 20% just from how the tube was handled before testing, which means the number on your report may not reflect what's actually happening inside your body.
That's the core tension with this particular lab value. CO₂ on a basic metabolic panel is really measuring bicarbonate, a buffer your blood uses to keep its pH stable. When it's genuinely low, it points to real problems. But it's also one of the more error-prone numbers on a routine panel, and interpreting it without context can lead you (or even your doctor) down the wrong path.
Sleep ApneaMar 15, 2026
For most people on positive airway pressure therapy, CPAP and BiPAP produce similar results on the outcomes that matter most: survival, avoiding intubation, and controlling sleep apnea. The research is consistent on this point across both acute hospital settings and long-term sleep disorder management. BiPAP isn't an upgrade from CPAP. It's a different tool, and the situations where it genuinely outperforms CPAP are more specific than many people realize.
The core difference is mechanical. CPAP (continuous positive airway pressure) pushes one steady pressure into your airway. BiPAP (bilevel positive airway pressure) delivers a higher pressure when you breathe in and a lower one when you breathe out. That second, lower pressure is what makes BiPAP feel easier to exhale against, and the higher inspiratory pressure can do extra work to help move air in and clear carbon dioxide.
Respiratory HealthMar 15, 2026
Carbon dioxide isn't just a waste gas you exhale. When levels drop too low in your arterial blood, your brain's blood vessels constrict, oxygen delivery to tissues falls, and in critically ill patients, the risk of death goes up. The medical term is hypocapnia: an arterial CO₂ level (PaCO₂) below roughly 35 mmHg, almost always caused by breathing faster or deeper than your body needs.
Most of the time, a mild and temporary drop in CO₂ is harmless. But in hospitals, operating rooms, and emergency settings, low CO₂ is consistently linked to worse outcomes. The research makes a strong case that keeping CO₂ in a normal range (about 35 to 45 mmHg) matters more than many people realize.
Sleep ApneaMar 15, 2026
Oral appliances reduce apnea severity less than CPAP on paper, yet they produce similar long-term treatment success in many people with mild to moderate obstructive sleep apnea. That counterintuitive finding captures something important about how OSA treatment actually works in real life: the best therapy is often the one you'll actually use, not the one with the most impressive numbers in a lab.
CPAP remains the gold standard for lowering the apnea-hypopnea index (AHI, the number of breathing disruptions per hour) and improving blood oxygen levels, particularly in severe OSA. But "gold standard" doesn't mean "only standard." A growing body of research supports several alternatives, each with distinct strengths, limitations, and ideal candidates.
Sleep ApneaMar 15, 2026
Inspire, the implanted device for obstructive sleep apnea, reduces the number of breathing disruptions per hour by roughly 50 to 57 percent, and people actually use it. Real-world data shows patients keep it on about 5.5 to 6 hours a night, on approximately 90 percent of nights. That adherence figure alone sets it apart from CPAP, the treatment most people with moderate-to-severe OSA are told to use first and many abandon.
But Inspire is not a universal fix. It works well for a carefully selected slice of the OSA population, and the selection criteria are strict for good reason. Here is what the research actually supports, who stands to benefit, and where the limits are.
Blood HealthMar 15, 2026
Most people think of carbon dioxide as a waste gas, something your body just needs to get rid of. But when CO₂ drops too low in your blood, it triggers a chain reaction that constricts blood vessels in your brain and heart, shifts how oxygen binds to your red blood cells, and ultimately reduces oxygen delivery to the organs that need it most. Low blood CO₂ is not a minor lab quirk. It is repeatedly associated with worse outcomes in heart failure, brain injury, stroke, major surgery, and critical illness.
The normal range for arterial CO₂ (called PaCO₂) sits between 35 and 45 mmHg. Hypocapnia, the medical term for low CO₂, generally means a PaCO₂ below 35 mmHg. Whether it shows up on an arterial blood gas or as low bicarbonate on a routine metabolic panel, it almost always points to something that deserves attention.
COPDMar 13, 2026
The most widely used system for staging COPD does a solid job separating severe from very severe disease, but it struggles to distinguish early-stage COPD from normal lung function. A newer alternative flips this strength: it catches the early changes more reliably but loses some precision at the advanced end. Neither system alone tells the full story, and understanding what each one actually measures puts you in a much better position to interpret your own results.
COPD staging isn't just a label. It shapes which treatments doctors recommend, how aggressively they monitor you, and what your likely trajectory looks like. But the staging landscape is more complicated than a single number, and the system your pulmonologist uses determines what gets captured and what gets missed.
AsthmaMar 13, 2026
Fluticasone propionate is one of the most potent inhaled corticosteroids available, and less than 1% of each dose makes it past your lungs into the rest of your body. That's a feature, not a bug. It means strong local anti-inflammatory action with minimal systemic side effects. But that same intense local potency creates a split personality: in asthma, it's a highly effective controller. In COPD, it helps with symptoms but raises a real pneumonia risk that other inhaled steroids don't seem to carry to the same degree.
Understanding where fluticasone shines and where it gets complicated is the difference between using it well and using it blindly.
